GB2441581B - Compositions and methods for the treatment of muscle wasting - Google Patents
Compositions and methods for the treatment of muscle wastingInfo
- Publication number
- GB2441581B GB2441581B GB0616790A GB0616790A GB2441581B GB 2441581 B GB2441581 B GB 2441581B GB 0616790 A GB0616790 A GB 0616790A GB 0616790 A GB0616790 A GB 0616790A GB 2441581 B GB2441581 B GB 2441581B
- Authority
- GB
- United Kingdom
- Prior art keywords
- compositions
- treatment
- methods
- muscle wasting
- wasting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010028289 Muscle atrophy Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 201000000585 muscular atrophy Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100777302A CN100393320C (en) | 2005-06-24 | 2005-06-24 | Oligonucleotide medicine for treating myophagism |
PCT/US2006/025657 WO2008005002A1 (en) | 2006-06-30 | 2006-06-30 | Compositions and methods for the treatment of muscle wasting |
Publications (3)
Publication Number | Publication Date |
---|---|
GB0616790D0 GB0616790D0 (en) | 2006-10-04 |
GB2441581A GB2441581A (en) | 2008-03-12 |
GB2441581B true GB2441581B (en) | 2011-01-19 |
Family
ID=39106232
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB0616790A Expired - Fee Related GB2441581B (en) | 2005-06-24 | 2006-06-30 | Compositions and methods for the treatment of muscle wasting |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB2441581B (en) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995035032A1 (en) * | 1992-05-22 | 1995-12-28 | The Scripps Research Institute | SUPPRESSION OF NUCLEAR FACTOR-kB DEPENDENT PROCESSES USING OLIGONUCLEOTIDES |
WO2003002739A1 (en) * | 2001-05-24 | 2003-01-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Antisense oligonucleotide against human acetylcholinesterase (ache) and uses thereof |
US6656475B1 (en) * | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
US20040038303A1 (en) * | 2002-04-08 | 2004-02-26 | Unger Gretchen M. | Biologic modulations with nanoparticles |
WO2004031350A2 (en) * | 2002-09-26 | 2004-04-15 | Amgen, Inc. | Modulation of forkhead box o1a expression |
US20050020541A1 (en) * | 2001-10-30 | 2005-01-27 | Reinhold Tacke | Silicon compounds |
US20050124566A1 (en) * | 2001-05-18 | 2005-06-09 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA) |
WO2006086667A2 (en) * | 2005-02-09 | 2006-08-17 | Avi Bio Pharma, Inc. | Antisense composition and method for treating muscle atrophy |
-
2006
- 2006-06-30 GB GB0616790A patent/GB2441581B/en not_active Expired - Fee Related
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995035032A1 (en) * | 1992-05-22 | 1995-12-28 | The Scripps Research Institute | SUPPRESSION OF NUCLEAR FACTOR-kB DEPENDENT PROCESSES USING OLIGONUCLEOTIDES |
US6656475B1 (en) * | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
US20050124566A1 (en) * | 2001-05-18 | 2005-06-09 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA) |
WO2003002739A1 (en) * | 2001-05-24 | 2003-01-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Antisense oligonucleotide against human acetylcholinesterase (ache) and uses thereof |
US20050020541A1 (en) * | 2001-10-30 | 2005-01-27 | Reinhold Tacke | Silicon compounds |
US20040038303A1 (en) * | 2002-04-08 | 2004-02-26 | Unger Gretchen M. | Biologic modulations with nanoparticles |
WO2004031350A2 (en) * | 2002-09-26 | 2004-04-15 | Amgen, Inc. | Modulation of forkhead box o1a expression |
WO2006086667A2 (en) * | 2005-02-09 | 2006-08-17 | Avi Bio Pharma, Inc. | Antisense composition and method for treating muscle atrophy |
Non-Patent Citations (2)
Title |
---|
American Journal of Physiology - Cell Physiology (2006); Vol 291, pp C538-C545, "Gene silencing of myostatin in different...", Sato et al * |
Expert Opinion on Emerging Drugs (2004); Vol 9, pp 345-361, "Emerging drugs for sarcopenia:age related muscle wasting", Lynch * |
Also Published As
Publication number | Publication date |
---|---|
GB0616790D0 (en) | 2006-10-04 |
GB2441581A (en) | 2008-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200607433B (en) | Methods and compositions for the treatment of gastroin-testinal disorders | |
IL181896A0 (en) | Methods and compositions for the treatment of hyperlipidemia | |
EP1737482A4 (en) | Compositions and methods for treating diseases | |
ZA200704677B (en) | Compositions and methods for the treatment of autism | |
IL196465A0 (en) | Compositions and methods for the treatment of mucositis | |
IL186973A0 (en) | Compositions and methods for treatment for neoplasms | |
IL191072A0 (en) | Therapeutic compositions and methods | |
IL186963A0 (en) | Methods and compositions for treating pain | |
EP1814575A4 (en) | Methods and compositions for treating conditions | |
EP1890712A4 (en) | Compositions and methods for treating pain | |
IL197804A0 (en) | Compositions for the trearment of hepatitis c and methods for using compositions for the treatment of hepatitis c | |
IL196843A0 (en) | Compositions and methods for the treatment of radiation proctosigmoitis | |
ZA200703087B (en) | Methods and compositions for the treatment of hyperlipidemia | |
GB0522460D0 (en) | Composition and method for the treatment of avian influenza | |
IL198723A0 (en) | Methods and compositions for therapeutic treatment | |
IL186325A0 (en) | Tizanidine compositions and methods of treatment using the compositions | |
IL189009A0 (en) | Methods and compositions for the treatment of neuropathies and related disorders | |
EP2124968A4 (en) | Compositions and methods for the treatment of muscle wasting | |
ZA200804500B (en) | Methods and compositions for the treatment of gastro-intestinal disorders | |
IL187405A0 (en) | Methods and compositions for the treatment of pain | |
EP1937075A4 (en) | Synergistic composition and method of use | |
EP1720563A4 (en) | Methods and compositions for the treatment of inflammation | |
EP1740221A4 (en) | Methods and compositions for the treatment of polycystic diseases | |
EP1904088A4 (en) | Compositions and methods for the treatment of cancer | |
EP1755581A4 (en) | Methods and compositions for the treatment of myocardial conditions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
COOA | Change in applicant's name or ownership of the application |
Owner name: OLIGOS ETC, INC. Free format text: FORMER APPLICANT(S): DALE, RODERIC M K |
|
732E | Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977) |
Free format text: REGISTERED BETWEEN 20100729 AND 20100804 |
|
PCNP | Patent ceased through non-payment of renewal fee |
Effective date: 20220630 |